34.30 0.00 (0.00%)
After hours: 4:49PM EDT
|Bid||34.27 x 800|
|Ask||34.31 x 800|
|Day's Range||32.50 - 34.35|
|52 Week Range||16.69 - 41.33|
|Beta (3Y Monthly)||1.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Medicines Company (NASDAQ: MDCO) stock has staged a nice recovery in the first half of 2019 after a steep 60% pullback in the second half of 2018 that dragged it to a 52-week low of $16.69 on Dec. 21. Medicines Co. is a biopharma with a single-point focus of tackling cardiovascular diseases. About 17.3 million deaths occur globally due to cardiovascular diseases, with 854,000 of these in the U.S., according to the company, which cited WHO estimates.
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.
Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.
(Bloomberg) -- Medicines Co. is nearing the finish line in its journey to introduce a new type of cholesterol medicine that analysts expect to top $4 billion a year in sales.A trio of late-stage studies over the next few months will show investors whether that target is achievable. The medicine, a twice-a-year injection called inclisiran, was designed as an add-on to statin therapy for high-risk patients who need something more powerful to reduce their LDL cholesterol. Medicines Co. estimates that at least 12.7 million patients in the U.S. could benefit.“There is a genuine belief in the value proposition and what this drug can bring,” chief executive Mark Timney said in an interview at the company’s Parsippany, New Jersey, headquarters. “Being able to lower LDL on top of existing therapies while at the same time giving you that guaranteed adherence” with twice-yearly dosing. Two-thirds of cholesterol patients now stop taking their drugs after a year, he said.Inclisiran’s use with other approved therapies could make Medicines Co. a prime takeout target for companies with cholesterol drugs that are looking to beef up their offerings.“It’s a logical bolt-on for these mega-caps that need assets that have struggled with innovation and filling their pipelines,” Chardan Capital Markets analyst Gbola Amusa said in an interview. “MedCo gives them that shiny new product that makes them look great.” He gave Eli Lilly & Co. and Pfizer Inc. as examples before Pfizer agreed to combine its old blockbusters with generic drugmaker Mylan NV.All 14 analysts following Medicines Co. recommend investors buy shares of the company. The average 12-month price target of $61 implies more than 60% upside from the stock’s last closing price. The company’s market value has already doubled since early January to $2.9 billion.While Wall Street has swooned over the prospect of a blockbuster heart drug and a potential multibillion-dollar deal, there are still skeptics. The stock’s short interest remains elevated, with 30% of shares available for trading sold short, according to financial analytics firm S3 Partners. However, some short sellers covered their positions this month with short bets declining by more than 1.6 million, S3’s Ihor Dusaniwsky said in an email.Medicines Co.’s $950 million in convertible debt could be attracting short-sellers but the stock also has a strong institutional following, according to Timney. Roughly 80% of the company’s shares are held by its ten largest holders, data compiled by Bloomberg show.“We’ve seen an increased investment from existing investors, and what we’ve seen is a lot of new investors are coming in or wanting to,” Timney said. “That was highlighted” by Medicines Co. raising about $150 million through an equity offering at the end of June. That will fund the drugmaker through the second-half of next year and cover its planned regulatory filings.“The last two quarters of this year will be critical as we approach filing for the U.S. and next year filing for Europe,” Timney said.To contact the reporter on this story: Bailey Lipschultz in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Catherine Larkin at email@example.com, Morwenna ConiamFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.
Medicines Co. (MDCO) delivered earnings and revenue surprises of 4.55% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.
John McCamant, editor of The Medical Technology Stock Letter, chose The Medicines Co. (MDCO) as his top speculative idea for 2019. The stock has since risen 90%. Here's his latest update on this biotechnology play.
Alnylam (ALNY) submits Marketing Authorization Application to the EMA for givosiran in development for the treatment of acute hepatic porphyria.
Health care companies featured prominently in the week's insider purchases. MGM Resorts International (NYSE: MGM) had a director continue to make indirect share purchases this past week. MGM stock rose about 2% in the past week, while the S&P 500 was essentially flat.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 24) Global Blood Therapeutics Inc (NASDAQ: GBT ) Krystal ...
Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.
Medicines Co NASDAQ/NGS:MDCOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for MDCO with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MDCO. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MDCO are favorable, with net inflows of $2.28 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.
The Medicines Company (NASDAQ: MDCO ) shares traded higher by 2.5 percent on Tuesday and are now up 7.5 percent overall in the past week. At this point, Medicines Company traders are likely considering ...